Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

(n)SPRAVATO® (esketamine)* Nasal Spray is Available for Canadian Patients

(n)SPRAVATO® (esketamine)* Nasal Spray is Available for Canadian Patients (CNW Group/Janssen Pharmaceutical Companies of Johnson & Johnson)

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Jul 22, 2020, 07:00 ET

Share this article

Share toX

Share this article

Share toX

A New Antidepressant with a Novel Mechanism of Action to Treat
Major Depressive Disorder in Adults

TORONTO, July 22, 2020 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that SPRAVATO® (esketamine), following a Notice of Compliance (NOC) from Health Canada, is now available for Canadian patients. SPRAVATO® nasal spray, the first glutamate receptor modulator approved for the treatment of major depressive disorder (MDD), is indicated for use in combination with an oral antidepressant (that is either a SSRI or SNRI**) for the treatment of MDD in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode.

MDD is a leading cause of disability worldwide1 and can have a profound impact on peoples' lives. In Canada, about 11 per cent of men and 16 per cent of women will experience major depression in the course of their lives.2 Although currently available antidepressants are effective for many patients, the symptoms of depression in up to one-third of patients do not adequately respond to treatment.3 

"Depression is a common and debilitating condition that can have a substantial impact on the emotional and functional well-being of those living with the condition as well as their loved ones. The impact of depression is most significant for those who have gone through multiple treatments without relief," said Dr. Roumen Milev, Vice President, Medical and Academic Affairs, Providence Care Hospital and Director, Centre for Neuroscience Studies, Queen's University, Kingston, Ontario. "In clinical trials, we saw SPRAVATO® provide a sustained improvement in symptoms of major depressive disorder. This new therapy has the potential to change the treatment paradigm for patients and their physicians."

The global SPRAVATO® clinical development program included one Phase 2 (n=108) and five Phase 3 (n=1,601) clinical trials with more than 1,700 patients. Health Canada's approval was based on two pivotal Phase 3 clinical trials; a short-term induction study and a long-term maintenance study.4

In the induction study, those who took SPRAVATO® and an oral antidepressant experienced a statistically significant improvement in depression symptoms at four weeks compared to those who received a placebo and an oral antidepressant.

Patients who participated in the long-term maintenance study who were in stable remission and continued treatment with SPRAVATO®, were 51 per cent less likely to relapse versus those who maintained a regimen of a placebo and an oral antidepressant.

"Mood Disorders Society of Canada is pleased that a new treatment option is available for adults with major depressive disorder who have failed multiple previous treatments," said Dave Gallson, National Executive Director, MDSC. "With 227 unique combinations of symptoms for someone with depression, new options that work in novel ways are essential."

To support safe and responsible use, SPRAVATO® must be administered by the patient under the direct supervision of a healthcare professional and is only available to patients through physicians and pharmacists enrolled in a controlled distribution program called the JANSSEN JOURNEY™ Program. 

About Major Depressive Disorder
MDD is a complex mood disorder caused by various factors, including genetic predisposition, personality, stress and brain chemistry.5 It is characterized by symptoms of a persistently low mood, changes in appetite and sleep, fatigue, loss of motivation, or feelings of worthlessness.6 It can also be associated with a substantial loss in productivity, quality of life and increased mortality from suicide.7

MDD affects more than 264 million people of all ages, globally.8 Although currently available antidepressants are effective for many patients, about one-third of patients do not adequately respond to treatment.9

About the SPRAVATO® Clinical Trial Program
SPRAVATO® nasal spray was evaluated for efficacy and safety in more than 1,700 adult patients (18 to 86 years) who met DSM–5 criteria for MDD and were non–responders to at least two oral antidepressants of adequate dosage and duration, in the current major depressive episode. The development program included five Phase 3 studies (three short-term and two long-term studies) and one Phase 2 dose-ranging study.10

In the Phase 3 program, the most commonly observed adverse reaction in patients treated with SPRAVATO® plus an oral antidepressant were dissociation (involving some degree of detachment from reality), dizziness, nausea, sedation, headache, vertigo, dysgeusia, hypoesthesia, increased blood pressure, anxiety and vomiting.11

About SPRAVATO®
SPRAVATO® nasal spray in combination with an oral antidepressant (that is either a SSRI or SNRI**) is indicated for the treatment of MDD in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode. SPRAVATO® works differently than currently available therapies for MDD. It works on the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor in the brain, which is a different mechanism of action than existing antidepressants.

SPRAVATO® builds on Janssen's more than 50-plus-year history and commitment to research that makes a difference for people living with mental illnesses, including severe mood disorders.

SPRAVATO® is self-administered as a nasal spray, under the supervision of a healthcare professional and is absorbed through the lining of the nasal passages.12

Please refer to the SPRAVATO® Product Monograph for complete prescribing information.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/canada. Follow us at www.twitter.com/JanssenCanada. Janssen Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

*All trademark rights used under license. 


** SSRI = Selective Serotonin Reuptake Inhibitor; SNRI = Serotonin-Norepinephrine Reuptake Inhibitor


***Dr. Milev was not compensated for any media work. He has been compensated as a consultant.


**** Dave Gallson was not compensated for any media work. Mood Disorders Society of Canada has received funds for patient engagement.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding SPRAVATO®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

References

_________________________

1 World Health Organization. Depression. Available at: http://www.who.int/mediacentre/factsheets/fs369/en/. Accessed May 5, 2020.

2 Health Canada. It's Your Health. Depress. Available at https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/hl-vs/alt_formats/pacrb-dgapcr/pdf/iyh-vsv/diseases-maladies/depression-eng.pdf. Accessed May 5, 2020.

3 US National Library of Medicine. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues in clinical neuroscience. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518696/.Accessed June 19, 2020

4 SPRAVATO® Product Monograph. Janssen Inc. Version date: May 19, 2020.

5 CAMH. Depression. https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/depression. Accessed May 5, 2020.

6 Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiatry. 2016;61(9):510-523

7 Bakish, D. The Journal of Clinical Psychiatry. New Standard of Depression Treatment: Remission and Full Recovery. J Clin Psychiatry. 2001;62 Suppl 26:5-9

8 World Health Organization. Depression. Available at: http://www.who.int/mediacentre/factsheets/fs369/en/. Accessed May 5, 2020.

9 US National Library of Medicine. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues in clinical neuroscience. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518696/.Accessed June 19, 2020

10 SPRAVATO™ Product Monograph. Janssen Inc. Version date: May 19, 2020.

11 SPRAVATO™ Product Monograph. Janssen Inc. Version date: May 19, 2020.

12 SPRAVATO™ Product Monograph. Janssen Inc. Version date: May 19, 2020.

SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson

Media Contact: Laura Espinoza, Office: (416) 382-5156; Investor Contact: Jennifer McIntyre, Office: (732) 524-3922

Modal title

Organization Profile

Janssen Pharmaceutical Companies of Johnson & Johnson

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.